Levi & Korsinsky Invites ALT Investors to Join Class Action Lawsuit by October 6, 2025
On August 22, 2025, Levi & Korsinsky, LLP announced that investors of Altimmune, Inc. (NASDAQ: ALT) could join a class action securities lawsuit related to alleged fraud. The lawsuit focuses on events that transpired between August 10, 2023 and June 25, 2025.
The class action aims to recover losses for Altimmune investors. It highlights issues stemming from a press release on June 26, 2025, where Altimmune disclosed disappointing results from its IMPACT Phase 2b trial of Pemvidutide, aimed at treating MASH (Metabolic Associated Steatotic Liver Disease). Leading up to these results, company executives had reportedly set inflated expectations, only for the trial analysis to show a significant failure to meet the primary endpoint for fibrosis reduction.
During the trial, a positive trend was observed in the improvement of fibrosis; however, the results were marred by an unexpectedly high placebo response. The company’s lack of transparency regarding these findings was questioned by investors, leading to widespread disappointment. After this critical announcement, Altimmune's stock price plummeted by 53.2%, dropping from $7.71 at market close on June 25, 2025, to $3.61 the following day. This dramatic decline exemplified the financial repercussions faced by investors based on misleading information provided by the company.
Joseph E. Levi, Esq., a representative from Levi & Korsinsky, reached out via email, stressing that those who incurred losses during the specified period should act promptly. Investors have until October 6, 2025, to apply for lead plaintiff status in this lawsuit. While becoming a lead plaintiff is an option, participation in the class does not require one to take on that role, and there are no out-of-pocket expenses for class members who wish to be included.
Levi & Korsinsky boasts a robust track record in securities litigation, having secured hundreds of millions for aggrieved shareholders over the past two decades. The firm emphasizes its commitment to ensuring that investors are not left to bear the financial burden of misrepresentation. With a well-respected position in the industry, the firm has been named one of the top securities litigation firms by ISS Securities Class Action Services for seven years consecutively.
If you are an Altimmune investor impacted by these events, now is the time to consider joining the class action suit. You can access further details through the provided link and will be contacted by a member of the team to discuss your potential involvement. Losing money on investments is never easy, but standing together with other affected shareholders can provide a pathway towards potential recovery and accountability for corporate actions.
For further inquiries or to submit your interest in participating, reach out to Levi & Korsinsky directly at their New York office. Investors deserve to have their voices heard and have the opportunity to take action against corporate misdeeds. Don't miss your chance to be part of this important legal initiative.
The class action aims to recover losses for Altimmune investors. It highlights issues stemming from a press release on June 26, 2025, where Altimmune disclosed disappointing results from its IMPACT Phase 2b trial of Pemvidutide, aimed at treating MASH (Metabolic Associated Steatotic Liver Disease). Leading up to these results, company executives had reportedly set inflated expectations, only for the trial analysis to show a significant failure to meet the primary endpoint for fibrosis reduction.
During the trial, a positive trend was observed in the improvement of fibrosis; however, the results were marred by an unexpectedly high placebo response. The company’s lack of transparency regarding these findings was questioned by investors, leading to widespread disappointment. After this critical announcement, Altimmune's stock price plummeted by 53.2%, dropping from $7.71 at market close on June 25, 2025, to $3.61 the following day. This dramatic decline exemplified the financial repercussions faced by investors based on misleading information provided by the company.
Joseph E. Levi, Esq., a representative from Levi & Korsinsky, reached out via email, stressing that those who incurred losses during the specified period should act promptly. Investors have until October 6, 2025, to apply for lead plaintiff status in this lawsuit. While becoming a lead plaintiff is an option, participation in the class does not require one to take on that role, and there are no out-of-pocket expenses for class members who wish to be included.
Levi & Korsinsky boasts a robust track record in securities litigation, having secured hundreds of millions for aggrieved shareholders over the past two decades. The firm emphasizes its commitment to ensuring that investors are not left to bear the financial burden of misrepresentation. With a well-respected position in the industry, the firm has been named one of the top securities litigation firms by ISS Securities Class Action Services for seven years consecutively.
If you are an Altimmune investor impacted by these events, now is the time to consider joining the class action suit. You can access further details through the provided link and will be contacted by a member of the team to discuss your potential involvement. Losing money on investments is never easy, but standing together with other affected shareholders can provide a pathway towards potential recovery and accountability for corporate actions.
For further inquiries or to submit your interest in participating, reach out to Levi & Korsinsky directly at their New York office. Investors deserve to have their voices heard and have the opportunity to take action against corporate misdeeds. Don't miss your chance to be part of this important legal initiative.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.